Fresenius SE & Co. KGaA (FSNUF)
51.89
0.00 (0.00%)
USD |
OTCM |
Dec 09, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 29.23B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 54.24% |
| Valuation | |
| PE Ratio | 22.95 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 1.184 |
| Price to Book Value | 1.336 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 1.137 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.727 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 75.38% |
Profile
| Fresenius SE & Co. KGaA is a healthcare group, which engages in the provision of products and services for dialysis, hospitals, and outpatient medical care. It operates through the following segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed. The Fresenius Medical Care segment caters to individuals with renal diseases. The Fresenius Kabi segment specializes in lifesaving medicines and technologies. The Fresenius Helios offers expertise in inpatient and outpatient care as well as in telemedicine. The Fresenius Vamed segment manages projects and services for hospitals and other healthcare facilities. The company was founded by Eduard Fresenius on October 1, 1912 and is headquartered in Bad Homburg, Germany. |
| URL | http://www.fresenius.de |
| Investor Relations URL | https://www.fresenius.com/investors |
| HQ State/Province | Hessen |
| Sector | Health Care |
| Industry | Health Care Providers & Services |
| Next Earnings Release | Feb. 25, 2026 (est.) |
| Last Earnings Release | Nov. 05, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | May. 27, 2025 |
Ratings
Profile
| Fresenius SE & Co. KGaA is a healthcare group, which engages in the provision of products and services for dialysis, hospitals, and outpatient medical care. It operates through the following segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed. The Fresenius Medical Care segment caters to individuals with renal diseases. The Fresenius Kabi segment specializes in lifesaving medicines and technologies. The Fresenius Helios offers expertise in inpatient and outpatient care as well as in telemedicine. The Fresenius Vamed segment manages projects and services for hospitals and other healthcare facilities. The company was founded by Eduard Fresenius on October 1, 1912 and is headquartered in Bad Homburg, Germany. |
| URL | http://www.fresenius.de |
| Investor Relations URL | https://www.fresenius.com/investors |
| HQ State/Province | Hessen |
| Sector | Health Care |
| Industry | Health Care Providers & Services |
| Next Earnings Release | Feb. 25, 2026 (est.) |
| Last Earnings Release | Nov. 05, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | May. 27, 2025 |